Video: Optometry Times® news summary 10/25/2020

Nora Lee Cothran, OD, FAAO, reviews a study which found a statistically significant reduction in IOP in patients with open-angle glaucoma and ocular hypertension when switching to latanoprostene bunod.

Dry eye questionnaires capture only 22.4% of Demodex blepharitis symptoms, and a 22-study review links Demodex infestation to worse meibomian gland function.

Real-world PFHO data show OSDI scores falling within 2 weeks, while a 12-month trial finds stable corneal endothelial cell density with cyclosporine 0.1%.

Christopher W. Lievens, OD, MS, PhD, FAAO, FNAP, FBCLA, discusses his poster presentation titled "Latanoprostene bunod 0.024% Initiation in Medicare Fee-for-Service Patients with Open Angle Glaucoma and Ocular Hypertension."

To kick off Perimenopause and Menopause Awareness Month, Meredith Bishop, OD, MS, FAAO, gives an overview of her poster "Perceptions of Linking Presbyopia with Perimenopause: A Survey of US Female Eye Care Professionals."

Michael Cymbor, OD, FAAO, gives an overview of a rapid fire lecture he gave in collaboration with Andrew Rixon OD, FAAO; Austin Lifferth, OD, FAAO; and Derek MacDonald, OD, FAAO, at AAOpt 2026.

Maria Sampalis, OD, tells Diana Canto-Sims, OD, in this week's episode that the biggest impact AI has made at her practice is when used in the exam room as a scribe for routine patients.

Aldeyra Therapeutics will submit a FDRR to the FDA for reproxalap, an investigational drug or dry eye disease.